A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Recruiting now · Phase 2

Conditions studied: T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma

In brief

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response

Key facts

Study ID
NCT06514794
Run by
Allotera Therapeutics
People needed
125
Starts
2025-01-31
Expected to finish
2028-12-30
Last updated by the study team
2026-08-06

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.